UK markets open in 6 hours 56 minutes

CureVac N.V. (CVAC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
93.96-4.01 (-4.09%)
At close: 4:00PM EDT

93.96 0.00 (0.00%)
After hours: 7:14PM EDT

Sign in to post a message.
  • #
    # Mike
    EMA JUST SAID THIS: We are very confident, and just waiting for the final results from Curevac to get the aproval...Curevac will be the next vaccine that will get approval...

    EMA says Novavax needs to be rediscussed...
  • P
    PETER
    The result of phase 3 will come out within week.
  • G
    Gurkan
    All the indicators and previously announced timelines were pointing out this week. What do you think guys, when will they announce the results in your opinion?
  • S
    SONG
    Last buying chance!?
  • S
    Sid
    Everything will depend on Phase 3 results. An efficacy of 80% plus will be awesome. Below that is Uh. Also, company must come with manufacturing volume and timeline. They still will have much limitation without a USA phase 3 study. IMHO. No position for me here.
  • L
    Late Night Stocks
    The approval is soon, we can see a stock price spike this Month. You can find more details in our fact-based analysis.
    Is CureVac still a BUY in 2021? | CVAC | Vaccine Stocks | mRNA | Biotech | Late Night Stocks
    www.youtube.com
  • #
    # Mike
    EMA CHMP Meeting is next week where it will happen https://www.ema.europa.eu/en/documents/other/chmp-meeting-dates-2021-2022-2023-2024_en.pdf
  • G
    Gino
    published Monday, a great audio interview with CVAC's co-founder. The subject of the interview is mRNA treatments for cancer. My French is reasonably good but I'd appreciate someone who is proficient/native to give a fuller description of what is said. The short of it is cancers have protein structures that we can teach the body to recognise and then fight off. But like with covid or with viruses in general the cancer can avade detection through mutations. This is where some key benefits of mRNA technology come in and in particular CVAC's strength. A personalised treatment can be devised for the patient within a matter of weeks and receive the mRNA treatment quickly thanks to the printer CVAC is developing. This is something CVAC clearly has a strength over rivals BNTX. So if mRNA tech is eventually proven to work against cancers then CVAC will be in a leading position to capitalise on it.
  • e
    edward
    I thought we were bringing news out last week ?
  • j
    jurin
    curevac calls to p3 participants and tell them they got vaccine or placebo

    this means curevac is not blind now

    result should come out this week
  • A
    Aad
    Are people ever looking beyond covid? Everything is extremely focused now and people are overreacting about every piece of covid news that comes out. Curevac is a solid company with a great pipeline and on the verge of making profits. I’m not even thinking about selling.
  • S
    Sid
    Everything depends on Phase 3👌🙏
  • S
    Sid
    CVAC and NVAX both depend on phase 3 results
  • G
    Gino
    CVAC have rejected suspension of their patents (along with BNTX). Will try and post the link
  • N
    Nick
    Angela Merkel opposes United States plan to require corona vaccine manufacturers to release their patents

    https://www.nu.nl/economie/6131899/duitse-bondskanselier-angela-merkel-tegen-vrijgave-patenten-op-coronavaccins.html
  • #
    # Mike
    @ Sid: you should rejoin tomorrow...
  • F
    Faramarz
    It looks like we hit some hurdles in CVAC vaccine program because of USA banning export of necessary raw materials
  • V
    Vratislav
    Today morning EU - 8.00 am - 8.30 am... + 6% 10 million euro traded ! Data release next week.
  • G
    Gino
    There are some good posts on the BNTX board: EU parliament voted down the waiver in Apr, India still hasn't approved the PFE/BNTX vaccine, BNTX patents registered in Germany etc.. The next stage in the waiver story is at the WTO where they will vote on it and even then the EU can go reject, go to court etc.. Chances of this having a meaningful impact in the short term (which is what the waiver is designed for) is neglible.
  • P
    PETER
    The clinical trial of NVAX fall behind schedule. Nvax and Cvac ,Both vaccine is available at room temperature. Now only one is left. CVAC